Authors’ Reply: Safety of combination therapy of azilsartan medoxomil and amlodipine: a population-based cohort study

Article information

Epidemiol Health. 2025;47.e2025054
Publication date (electronic) : 2025 September 20
doi : https://doi.org/10.4178/epih.e2025054
1Department of Medical Informatics, Kangwon National University College of Medicine, Chuncheon, Korea
2School of Pharmacy, Sungkyunkwan University, Suwon, Korea
3School of Pharmacy, Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan
4Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA
5DSC Investment, Seoul, Korea
6Division of Cardiology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea
Correspondence: Hyesung Lee Department of Medical Informatics, Kangwon National University College of Medicine, 1 Kangwondaehak-gil, Chuncheon 24341, Korea E-mail: hs.lee@kangwon.ac.kr
Received 2025 August 18; Accepted 2025 August 22.

Dear Editor,

We appreciate the thoughtful letter from Dr. Zhanyi Zhou regarding our recent study [1] on the safety of azilsartan medoxomil and amlodipine combination therapy in patients with hypertension. We thank the author for emphasizing the clinical importance of evaluating safety, specifically in patients with hypertension and concomitant heart failure.

While our study rigorously adjusted for multiple comorbidities, including chronic liver disease, chronic obstructive pulmonary disease, diabetes, and cerebrovascular and coronary artery disease, we acknowledge that heart failure was not included as a baseline covariate. This limitation was due to the lack of information on key clinical variables, such as New York Heart Association functional class and ejection fraction. However, given the new-user, active-comparator design and the robust adjustment for numerous relevant confounders, we expect that the prevalence and impact of heart failure would have been comparable between the treatment groups [2]. Furthermore, the relatively small sample size in the azilsartan medoxomil group and the anticipated low proportion of patients with heart failure limited our ability to perform a meaningful subgroup analysis by heart failure status in this study.

Considering the central role of angiotensin II receptor blockers in the management of both hypertension and guideline-directed heart failure, explicitly evaluating safety outcomes in patients with hypertension and concomitant heart failure would indeed provide valuable clinical guidance [3]. We fully support the recommendation that future studies incorporate such subgroup analyses to enhance the generalizability and clinical relevance of safety data across both general and high-risk populations.

Notes

Ethics statement

This article does not contain any studies with human participants or animals performed by any of the authors.

Conflict of interest

The authors have no conflicts of interest to declare for this study.

Funding

None.

Acknowledgements

None.

Author contributions

Conceptualization: Lee H, Hong B, Su CTT, Bea S, Jeong HE, Jung K, Cheng MCY, Chang ZCJ, Lai ECC, Lee J. Data curation: Lee H. Formal analysis: Hong B. Funding acquisition: Lee H. Methodology: Lee H, Hong B, Su CTT, Bea S, Jeong HE, Jung K, Cheng MCY, Chang ZCJ, Lai ECC, Lee J. Project administration: Lee H. Visualization: Hong B. Writing – original draft: Lee H, Hong B. Writing – review & editing: Lee H, Hong B, Su CTT, Bea S, Jeong HE, Jung K, Cheng MCY, Chang ZCJ, Lai ECC, Lee J.

References

1. Lee H, Hong B, Su CT, Bea S, Jeong HE, Jung K, et al. Safety of combination therapy of azilsartan medoxomil and amlodipine: a population-based cohort study. Epidemiol Health 2025;47e2025029. https://doi.org/10.4178/epih.e2025029.
2. Patorno E, Gopalakrishnan C, Franklin JM, Brodovicz KG, Masso-Gonzalez E, Bartels DB, et al. Claims-based studies of oral glucose-lowering medications can achieve balance in critical clinical variables only observed in electronic health records. Diabetes Obes Metab 2018;20:974–984. https://doi.org/10.1111/dom.13184.
3. Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. Circulation 2022;145:e895–e1032. https://doi.org/10.1161/CIR.0000000000001063.

Article information Continued